Cardiovascular Disease in Diabetes and Chronic Kidney Disease

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Nov 25

PMID 38002599

Authors

Sowmya Swamy

Sahibzadi Mahrukh Noor

Roy O Mathew

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease (CKD) is a common occurrence in patients with diabetes mellitus (DM), occurring in approximately 40% of cases. DM is also an important risk factor for cardiovascular disease (CVD), but CKD is an important mediator of this risk. Multiple CVD outcomes trials have revealed a greater risk for CVD events in patients with diabetes with CKD versus those without. Thus, reducing the risk of CKD in diabetes should result in improved CVD outcomes. To date, of blood pressure (BP) control, glycemic control, and inhibition of the renin-angiotensin system (RASI), glycemic control appears to have the best evidence for preventing CKD development. In established CKD, especially with albuminuria, RASI slows the progression of CKD. More recently, sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide receptor agonists (GLP1RA) have revolutionized the care of patients with diabetes with and without CKD. SGLT2i and GLP1RA have proven to reduce mortality, heart failure (HF) hospitalizations, and worsening CKD in patients with diabetes with and without existing CKD. The future of limiting CVD in diabetes and CKD is promising, and more evidence is forthcoming regarding combinations of evidence-based therapies to further minimize CVD events.

Citing Articles

Association of aberrant mineral metabolic markers with fracture risk in chronic kidney disease: a comprehensive meta-analysis.

Liu Y, Zhang Z, Fu C, Ye Z, Jin H, Yang X BMC Nephrol. 2025; 26(1):68.

PMID: 39934684 PMC: 11818153. DOI: 10.1186/s12882-025-03992-w.

Evaluating Risk Factors and the Burden of Silent Myocardial Ischemia Among Diabetic Patients.

Arshad M, Hassan M, Tahir M, Nawaz Khan M, Gultasib M, Ali G Cureus. 2024; 16(11):e74341.

PMID: 39583612 PMC: 11585965. DOI: 10.7759/cureus.74341.

Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.

Raza F, Altaf R, Bashir T, Asghar F, Altaf R, Tousif S Medicine (Baltimore). 2024; 103(44):e40364.

PMID: 39496023 PMC: 11537668. DOI: 10.1097/MD.0000000000040364.

A Comparative Analysis of the SARC-F Questionnaire and the Malnutrition-Inflammation Score for Sarcopenia Risk Assessment and Negative Outcome Probability in Chronic Hemodialysis Patients.

Katalinic L, Juric I, Furic Cunko V, Premuzic V, Jelakovic B, Basic-Jukic N J Clin Med. 2024; 13(18).

PMID: 39337040 PMC: 11432496. DOI: 10.3390/jcm13185554.

Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta‑analysis.

Qian H, Li S, Hu Z Oncol Lett. 2024; 28(5):514.

PMID: 39247494 PMC: 11378011. DOI: 10.3892/ol.2024.14648.

References

Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

Branch M, German C, Bertoni A, Yeboah J . Incremental risk of cardiovascular disease and/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial. J Diabetes Complications. 2019; 33(7):468-472. DOI: 10.1016/j.jdiacomp.2019.04.004. View

Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-34. DOI: 10.1056/NEJM199807233390404. View

. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022; 102(5S):S1-S127. DOI: 10.1016/j.kint.2022.06.008. View

Fraccarollo D, Galuppo P, Schraut S, Kneitz S, van Rooijen N, Ertl G . Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension. 2008; 51(4):905-14. DOI: 10.1161/HYPERTENSIONAHA.107.100941. View

Mercurio V, Lobasso A, Barbieri L, Parrella P, Ciervo D, Liccardo B . Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients. Int J Mol Sci. 2019; 20(9). PMC: 6540240. DOI: 10.3390/ijms20092154. View

de Zeeuw D, Remuzzi G, Parving H, Keane W, Zhang Z, Shahinfar S . Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004; 110(8):921-7. DOI: 10.1161/01.CIR.0000139860.33974.28. View

. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S144-S174. DOI: 10.2337/dc22-S010. View

Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364(9):829-841. PMC: 4109980. DOI: 10.1056/NEJMoa1008862. View

10.

Wu Y, Lin H, Tao Y, Xu Y, Chen J, Jia Y . Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease. Front Pharmacol. 2022; 13:967317. PMC: 9523214. DOI: 10.3389/fphar.2022.967317. View

11.

Keane W, Brenner B, de Zeeuw D, Grunfeld J, McGill J, Mitch W . The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003; 63(4):1499-507. DOI: 10.1046/j.1523-1755.2003.00885.x. View

12.

Matsushita K, van der Velde M, Astor B, Woodward M, Levey A, de Jong P . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073-81. PMC: 3993088. DOI: 10.1016/S0140-6736(10)60674-5. View

13.

Sung F, Jong Y, Muo C, Hsu C, Tsai W, Hsu Y . Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan. Front Pharmacol. 2022; 13:815882. PMC: 8930832. DOI: 10.3389/fphar.2022.815882. View

14.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

15.

Fellstrom B, Jardine A, Schmieder R, Holdaas H, Bannister K, Beutler J . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14):1395-407. DOI: 10.1056/NEJMoa0810177. View

16.

Cushman W, Evans G, Byington R, Goff Jr D, Grimm Jr R, Cutler J . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575-85. PMC: 4123215. DOI: 10.1056/NEJMoa1001286. View

17.

Beddhu S, Chertow G, Greene T, Whelton P, Ambrosius W, Cheung A . Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. J Am Heart Assoc. 2018; 7(18):e009326. PMC: 6222943. DOI: 10.1161/JAHA.118.009326. View

18.

Krane V, Wanner C . Statins, inflammation and kidney disease. Nat Rev Nephrol. 2011; 7(7):385-97. DOI: 10.1038/nrneph.2011.62. View

19.

Arshad A, Sarween N, Sharif A . Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR. Kidney Int Rep. 2021; 6(9):2415-2424. PMC: 8418973. DOI: 10.1016/j.ekir.2021.06.029. View

20.

Rossing P, Baeres F, Bakris G, Bosch-Traberg H, Gislum M, Gough S . The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023; 38(9):2041-2051. PMC: 10469096. DOI: 10.1093/ndt/gfad009. View